Xencor Inc XNCR
Xencor Inc (Nasdaq: XNCR) is an oncology drug developer. Its lead program, XmAb819 (ENPP3 x CD3), is in Phase 1 for Clear cell renal cell carcinoma (ccRCC).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| XmAb942 (Xtend TL1A) | Ulcerative colitis (UC) | antibody | Phase 2 |
| XmAb819 (ENPP3 x CD3) | ccRCC and ENPP3+ tumors | antibody | Phase 1 |
| XmAb541 (CLDN6 x CD3) | High-grade serous ovarian cancer, germ cell tumors | antibody | Phase 1 |
| XmAb808 (B7-H3 x CD28) | CLDN6+ tumors (combination with XmAb541) | antibody | Phase 1 |
| XmAb412 (TL1A x IL-23p19) | Autoimmune/inflammatory disease | antibody | Phase 1 |
| Plamotamab (CD20 x CD3) | Rheumatoid arthritis (RA) | antibody | Phase 1 |
| XmAb657 (CD19 x CD3) | Idiopathic inflammatory myopathies, systemic sclerosis, Sjögren's disease | antibody | Phase 1 |
Recent results and decisions
- Oct 26, 2026positive XmAb819 Phase 1 dose expansion reported 45.5% confirmed objective response rate at 400 mcg/kg IV target dose in heavily pre-treated advanced ccRCC patients.
400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate.
Filing - Oct 1, 2026positive XmAb819 achieved 45.5% confirmed objective response rate at 400 mcg/kg IV dose in advanced ccRCC patients.
As of the October 1, 2026, data-cut, the efficacy-evaluable cohort at the 400 mcg/kg intravenous (IV) dose (n=11) reported five confirmed partial responses for a confirmed objective response rate of 45.5% per investigator assessment (RECIST v1.1).
Filing - Sep 1, 2026positive XmAb819 achieved 45% confirmed ORR and 82% disease control rate at 400 mcg/kg IV target dose in heavily pre-treated advanced ccRCC patients.
400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.